Charles joined SV in 2018 and is a Principal in the biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage public and private opportunities. Charles serves as a Board Director at Imbria Pharmaceuticals and Mestag Therapeutics, which he also helped incubate and launch. He is also Board Observer at Autifony Therapeutics, EnaraBio, and Pulmocide.
Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies and has an academic background in human genetics & molecular biology (UCL).
Outside of SV, Charles is a keen chef, swimmer, and traveller.
Academic Credentials:
MSci Human Genetics, University College London (UCL). Chartered accountant (ACA).
